MFA Certifies First MulteFire Device and Base Station to Enable Private Networks in Unlicensed Spectrum
9.9.2021 17:43:00 EEST | Business Wire | Press release
MFA, an international organization championing the global industry adoption of private networks, is gaining industry momentum with the recent certification of the Nokia Industrial MulteFire fieldrouter 700 and announcement of Uni5G Technology Blueprints. The Nokia MulteFire solution, which is available for deployment with Nokia Digital Automation Cloud, will enable MulteFire LTE-based private network adoption worldwide, unlocking access to unlicensed spectrum. With deployment available globally, it can be used by small and medium enterprises without access to licensed spectrum and it can bring additional capacity as a complementary layer to wireless networks and enable new nomadic use cases to advance Industry 4.0.
In addition to supporting 4.9G/LTE private networks, MFA recently announced its expansion to 5G with Uni5G Technology Blueprints, which help provide guidance to enterprises looking to deploy 5G private networks. MFA is also developing best practices and targeted guides to help industry verticals implement the key 3GPP 5G specification features that are relevant to their specific deployment.
The MFA Certification Program ensures that devices have implemented the MulteFire specifications correctly and are able to interoperate with devices from other manufacturers.
“The Nokia MulteFire solution has passed rigorous interoperability testing at our Authorized Test Lab DEKRA,” said Scott Fischel, MFA Certification Group Chair. “We congratulate Nokia on delivering the world’s first MulteFire Certified end-to-end solution that will provide end-users with confidence that it can meet the robust connectivity requirements offered by MulteFire 4.9G/LTE private wireless.”
“Private 5G and LTE networks are a rapidly growing market and will account for over $5B in global enterprise expenditure by 2025,” said Pablo Tomasi, Principal Analyst, Private Networks, Omdia. “MFA aims to support and accelerate the private 5G networks market through both this certification program and by tackling the issue of replicability and complexity through the delivery of Uni5G Technology Blueprints developed to simplify deployment for different industry verticals.”
The MFA Certification Program is available to MFA members, and it will help facilitate further expansion of the MulteFire private wireless ecosystem. For companies interested in joining the MFA, visit www.mfa-tech.org/become-a-member.
Resources:
- Interview: Meet MFA Certificate Authority
- Interview: Meet MFA Authorized Test Lab – DEKRA
- Video: Uni5G and MulteFire Private Networks for Manufacturing
- Press Release: MulteFire Alliance (MFA) Simplifies Path to 5G Private Network Deployment for Enterprise
- White Paper: “5G Private Networks for Maritime Use Opportunities for Digital Port Automation,” Beecham Research
- White Paper: “The Importance of Spectrum Liberalization for Private 5G Networks,” ABI Research
About MFA
MFA is an international organization that is championing the global industry adoption of private networks using MFA-defined MulteFire specifications for LTE and Uni5G Technology Blueprints for 5G. With Uni5G or MulteFire, enterprises can efficiently deploy their own optimized, reliable and secure private network in unlicensed, shared or locally licensed spectrum. For more information, visit www.mfa-tech.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005742/en/
Contact information
MFA
Lori Mesecke, +1-503-459-9150
press@multefire.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions, expands our addressable market — more than doubling our revenue opportunity per gigawatt of delivered capacity — and allows us to scale both our offerings and the globa
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom